Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Bevacizumab Dexamethasone Verteporfin Photodynamic Therapy

Related Conditions

Often studied with 18 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1/2 (1)
Phase 3 (1)

Trial Status

Withdrawn2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00407121Phase 3Withdrawn

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

NCT01256580Not ApplicableWithdrawn

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

NCT00470977Phase 1/2Completed

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

Showing all 3 trials

Research Network

Common Treatments

  • Bevacizumab Dexamethasone Verteporfin Photodynamic Therapy1
  • Intravitreal Injection Of Bevacizumab1
  • Ranibizumab1
  • Bevacizumab Avastin Genentech Inc1
  • Bevacizumab1

Active Sponsors

  • Asociación para Evitar la Ceguera en México1
  • Genentech, Inc.1
  • Manhattan Eye, Ear & Throat Hospital1
  • Massachusetts Eye and Ear Infirmary1

Top Investigators

Related Conditions

  • Idiopathic Retinal Telangiectasia1
  • Best Vitelliform Macular Dystrophy Multifocal Disorder1
  • Angioid Streaks1
  • Rubeosis Iridis1
  • Choroidal Neovascularization1

Activity Timeline